The effect of tamoxifen as an adjuvant therapy for breast cancer on apolipoproteins and lipoprotein(a) concentrations in women: A meta-analysis of randomized controlled trials.

Autor: Zhang B; Department of Pharmacy, General Hospital of Central Theater Command, Wuhan 430010, China., Huang Y; Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan 430010, China., Zhang J; Department of Pharmacy, General Hospital of Central Theater Command, Wuhan 430010, China., Fu W; Cardiovascular Medicine, General Hospital of Central Theater Command, Wuhan 430010, China., Prabahar K; Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia., Hernández-Wolters B; University Center for Health Science, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico., Hu H; Department of Pharmacy, General Hospital of Central Theater Command, Wuhan 430010, China. Electronic address: ydiyaya@163.com., Hao F; Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan 430010, China. Electronic address: simple0027@sohu.com.
Jazyk: angličtina
Zdroj: Experimental gerontology [Exp Gerontol] 2024 Nov; Vol. 197, pp. 112587. Date of Electronic Publication: 2024 Oct 11.
DOI: 10.1016/j.exger.2024.112587
Abstrakt: Background and Aim: Tamoxifen has been used in the management of breast cancer. The available evidence on the effect of tamoxifen on lipoprotein(a) and apolipoproteins is controversial. Hence, this meta-analysis of randomized controlled trials (RCTs) was conducted to increase the quality of evidence on the effect of tamoxifen on lipoprotein(a) and apolipoproteins.
Methods: Eligible RCTs published up to September 2023 were carefully selected following a comprehensive search. Thereafter, a meta-analysis was conducted using a random-effects model and the results were presented as the weighted mean difference (WMD) with a 95 % confidence interval (CI).
Results: The results from the random-effects model indicated a rise in ApoA-I (WMD: 16.24 mg/dL, 95 % CI: 5.35, 27.12, P = 0.003), and a decrease in ApoB (WMD: -9.37 mg/dL, 95 % CI: -15.16, -3.59, P = 0.001) and lipoprotein(a) (WMD: -3.24 mg/dL, 95 % CI: -5.66, -0.83, P < 0.001) concentrations following tamoxifen administration in women. Furthermore, a more pronounced decrease in ApoB (WMD: -12.86 mg/dL, 95 % CI: -19.78, -5.93, P < 0.001) and elevation in ApoA-1 levels (WMD: 51.97 mg/dL, 95 % CI: 45.89, 58.05, P < 0.001) were identified in a single study on patients with breast cancer.
Conclusion: The current meta-analysis demonstrated an increase of ApoA-I and a decrease of ApoB and lipoprotein(a) levels after treatment with tamoxifen in women.
Competing Interests: Declaration of competing interest There was no conflict of interest declared by the authors.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: